Nutlin-3a (RG7112), an MDM2 inhibitor, has shown efficacy in reducing tumor growth, inducing apoptosis, and inhibiting cellular proliferation and hormone production in ACC models, especially those with CTNNB1 mutations (57). Here, MDM2 is linked to adrenal cortex carcinoma.